Merck KGaA shareholders rewarded for hard work of turning company around

Merck KGaA Chairman Karl-Ludwig Kley is feeling pretty good about the hard work his company has accomplished in the last three years or so. A tough series of job cuts helped it exceed cost-cutting goals. It has a new pact with Pfizer ($PFE) in the fast-emerging field of immuno-oncology for its anti-PD-L1 program that is worth up to $2.85 billion. That came on top of its $2.6 billion M&A move to gain control of AZ Electronic Materials and its much larger $17 billion buyout of chemical and lab equipment maker Sigma-Aldrich ($SIAL). With its stock price exceeding the market in growth and running around €100 a share, the company today suggested shareholdes reward themselves with a 5.3% dividend increase to €1 a share, something they quickly approved. Announcement | More

Suggested Articles

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.

This week, Goldman Sachs resurrected a burning question: How can pharma companies profit from curing patients with one-time gene and cell therapies?

CMS has determined how it'll pay for Gilead's CAR-T cancer therapy, Yescarta, for outpatient use, but hasn't yet decided on Gilead's…